3 results
In this study we want to determine the activity and safety of concurrent interruption of the MAPK and PI3K pathways by the EGFR tyrosine kinase inhibitor erlotinb and metformin, combined with gemcitabine in patients with metatastatic pancreatic…
To compare the efficacy of two dose levels of erlotinib (150 mg and 300 mg) on progression-free survival (PFS) in current smokers with stage IIIB/IV NSCLC after failure of first-line platinum-based chemotherapy.
Primary objectives:A. To determine the ability of the Toric ARTIFLEX PIOL to reduce astigmatism (performance); B. To establish the mechanical properties of the lens in the anterior chamber in terms of rotational stability of the lens, tilting of the…